Yıl: 2017 Cilt: 47 Sayı: 5 Sayfa Aralığı: 1509 - 1519 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Thyroid malignancy risk in different clinical thyroid diseases

Öz:
Background/aim: To evaluate the malignancy risk of thyroid nodules in different clinical thyroid diseases. Materials and methods: Patients who underwent thyroidectomy between 2007 and 2014 were grouped as euthyroid, hypothyroid, and hyperthyroid. Further classification was made depending on the presence of solitary/multiple thyroid nodules. Results: Among 2870 patients, 1719 (59.9%) were euthyroid, 962 (33.5%) were hyperthyroid, and 189 (6.6%) were hypothyroid. Overall malignancy was detected in 980 (34.1%) patients. Malignancy rates were 42.1%, 42.9%, and 18.3% in the euthyroid, hypothyroid, and hyperthyroid groups, respectively (P < 0.001). A total 41.4% of patients with euthyroid nodular goiter (ENG) and 46.3% of patients with euthyroid multinodular goiter (EMNG) had thyroid malignancy (P = 0.169). Mean tumor size and capsular and vascular invasion were significantly lower in EMNG than in ENG. Among hypothyroid patients, 45.7% with solitary and 42.2% with multiple nodules were malignant (P = 0.705). When toxic nodular goiter and toxic multinodular goiter were analyzed together, malignancy rate was 24.7% (104/421), and when Graves with nodule/nodules was considered, it was 19.7% (59/299). Conclusion: In hypothyroid or euthyroid patients who underwent thyroidectomy, malignancy rate was higher than 40%, and was lower in hyperthyroid patients. Patients with multiple nodules carry a similar risk of malignancy as patients with solitary nodules, independent of the functional status.
Anahtar Kelime:

Konular: Cerrahi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM et al. American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26: 1-133.
  • 2. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014; 140: 317-322.
  • 3. Hegedus L. Clinical practice. The thyroid nodule. N Engl J Med 2004; 351: 1764-1771.
  • 4. Gelmini R, Franzoni C, Pavesi E, Cabry F, Saviano M. Incidental thyroid carcinoma (ITC): a retrospective study in a series of 737 patients treated for benign disease. Ann Ital Chir 2010; 81: 421-427.
  • 5. Polyzos SA, Kita M, Efstathiadou Z, Poulakos P, Slavakis A, Sofianou D, Flaris N, Leontsini M, Kourtis A, Avramidis A. Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. J Cancer Res Clin Oncol 2008; 134: 953-960.
  • 6. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. Clin Endocrinol Metab 2008; 93: 809-814.
  • 7. Rago T, Fiore E, Scutari M, Santini F, Di Coscio G, Romani R. Male sex, single nodularity, and young age are associated with the risk of finding a papillary thyroid cancer on fine-needle aspiration cytology in a large series of patients with nodular thyroid disease. Eur J Endocrinol 2010; 162: 763-770.
  • 8. Jena A, Patnayak R, Prakash J, Sachan A, Suresh V, Lakshmi AY. Malignancy in solitary thyroid nodule: a clinicoradiopathological evaluation. Indian J Endocrinol Metab 2015; 19: 498-503.
  • 9. Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F, Panunzi C, Rinaldi R, Toscano V, Pacella CM. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 2002; 87: 1941-1946.
  • 10. Belfiore A, La Rosa GL, La Porta GA, Giuffrida D, Milazzo G, Lupo L, Regalbuto C, Vigneri R. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age and multinodularity. Am J Med 1992; 93: 363-369.
  • 11. Balasubramaniam S, Ron E, Gridley G, Schneider AB, Brenner AV. Association between benign thyroid and endocrine disorders and subsequent risk of thyroid cancer among 4.5 million U.S. male veterans. See comment in PubMed Commons belowJ Clin Endocrinol Metab 2012; 97: 2661-2669.
  • 12. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 2006; 91: 4295-4301.
  • 13. Gul K, Ozdemir D, Dirikoc A, Oguz A, Tuzun D, Baser H, Ersoy R, Cakir B. Are endogenously lower serum thyroid hormones new predictors for thyroid malignancy in addition to higher serum thyrotropin? Endocrine 2010; 37: 253-260.
  • 14. Gandolfi PP, Frisina A, Raffa M, Renda F, Rocchetti O, Ruggeri C, Tombolini A. The incidence of thyroid carcinoma in multinodular goiter: retrospective analysis. Acta Biomed 2004; 75: 114-117.
  • 15. Lin JD, Chao TC, Huang BY, Chen ST, Chang HY, Hsueh C. Thyroid cancer in the thyroid nodules evaluated by ultrasonography and fine-needle aspiration cytology. Thyroid 2005; 15: 708-717.
  • 16. McCall A, Jarosz H, Lawrence AM, Paloyan E. The incidence of thyroid carcinoma in solitary cold nodules and in multinodular goiters. Surgery 1986; 100: 1128-1132.
  • 17. Smith D, Thompson AM. Breast and endocrine surgery. In: Lavelle-Jones M, Dent JA, editors. Surgery. Toronto, ON, Canada: Elsevier, 2008. p. 119-141.
  • 18. Shi L, Li Y, Guan H, Li C, Shi L, Shan Z, Teng W. Usefulness of serum thyrotropin for risk prediction of differentiated thyroid cancers does not apply to microcarcinomas: results of 1,870 Chinese patients with thyroid nodules. Endocr J 2012; 59: 973- 980.
  • 19. Fiore E, Vitti P. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab 2012; 97: 1134-1145.
  • 20. Gupta KL. Neoplasm of the thyroid gland. Clin Geriatr Med 1995; 11: 271-290.
  • 21. Miccoli P, Minuto MN, Galleri D, D’Agostino J, Basolo F, Antonangeli L, Aghini-Lombardi F, Berti P. Incidental thyroid carcinoma in a large series of consecutive patients operated on for benign thyroid disease. ANZ J Surg 2006; 76: 123-126.
  • 22. Anil C, Goksel S, Gursoy A. Hashimoto’s thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study. Thyroid 2010; 20: 601-606.
  • 23. Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A, Shah JP. Coexistent Hashimoto’s thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery 1999; 126: 1070-1076.
  • 24. Lun Y, Wu X, Xia Q, Han Y, Zhang X, Liu Z, Wang F, Duan Z, Xin S, Zhang J. Hashimoto’s thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis. Otolaryngol Head Neck Surg 2013; 148: 396-402.
  • 25. Baser H, Ozdemir D, Cuhaci N, Aydin C, Ersoy R, Kilicarslan A, Cakir B. Hashimoto’s thyroiditis does not affect ultrasonographical, cytological, and histopathological features in patients with papillary thyroid carcinoma. Endocr Pathol 2015; 26: 356-364.
  • 26. Kim WB, Han SM, Kim TY, Nam-Goong IS, Gong G, Lee HK, Hong SJ, Shong YK. Ultrasonographic screening for detection of thyroid cancer in patients with Graves’ disease. Clin Endocrinol 2004; 60: 719-725.
  • 27. Faggiano A, Del Prete M, Marciello F, Marotta V, Ramundo V, Colao A. Thyroid diseases in elderly. Minerva Endocrinol 2011; 36: 211-231.
  • 28. Carnell NE, Valente WA. Thyroid nodules in Graves’ disease: classification, characterization, and response to treatment. Thyroid 1998; 8: 647-652.
  • 29. Mishra A, Mishra SK. Thyroid nodules in Graves’ disease: implications in an endemically iodine deficient area. J Postgrad Med 2001; 47: 244-247.
  • 30. Kang AS, Grant CS, Thompson GB, van Heerden JA. Current treatment of nodular goiter with hyperthyroidism (Plummer’s disease): surgery versus radioiodine. Surgery 2002; 132: 916- 923.
  • 31. Negro R, Valcavi R, Toulis KA. Incidental thyroid cancer in toxic and nontoxic goiter: is TSH associated with malignancy rate? Results of a meta-analysis. Endocr Pract 2013; 19: 212- 218.
  • 32. Preece J, Grodski S, Yeung M, Bailey M, Serpell J. Thyrotoxicosis does not protect against incidental papillary thyroid cancer. Surgery 2014; 156: 1153-1156.
  • 33. Pazaitou-Panayiotou K, Michalakis K, Paschke R. Thyroid cancer in patients with hyperthyroidism. Horm Metab Res 2012; 44: 255-262.
  • 34. Gul K, Di Ri Koc A, Ki Yak G, Ersoy PE, Ugras NS, Ozdemir D, Ersoy R, Cakir B. Thyroid carcinoma risk in patients with hyperthyroidism and role of preoperative cytology in diagnosis. Minerva Endocrinol 2009; 34: 281-288.
  • 35. Ren M, Wu MC, Shang CZ, Wang XY, Zhang JL, Cheng H, Xu MT, Yan L. Predictive factors of thyroid cancer in patients with Graves’ disease. World J Surg 2014; 38: 80-87.
  • 36. Pacini F, Elisei R, Di Coscio GC, Anelli S, Macchia E, Concetti R, Miccoli P, Arganini M, Pinchera A. Thyroid carcinoma in thyrotoxicosis patients treated by surgery. J Endocrinol Invest 1988; 11: 107-112.
  • 37. Cappelli C, Braga M, De Martino E, Castellano M, Gandossi E, Agosti B, Cumetti D, Pirola I, Mattanza C, Cherubini L et al. Outcome of patients surgically treated for various forms of hyperthyroidism with differentiated thyroid cancer: experience at an endocrine center in Italy. Surg Today 2006; 36: 125-130.
  • 38. Edmonds CJ, Tellez M. Hyperthyroidism and thyroid cancer. Clin Endocrinol (Oxf) 1998; 28: 253-259.
  • 39. Yano Y, Shibuya H, Kitagawa W, Nagahama M, Sugino K, Ito K, Ito K. Recent outcome of Graves’ disease patients with papillary thyroid cancer. Eur J Endocrinol 2007; 157: 325-329.
  • 40. Belfiore A, Garofalo MR, Giuffrida D, Runello F, Filetti S, Fiumara A. Increased aggressiveness of thyroid cancer in patients with Graves’ disease. J Clin Endocrinol Metab 1990; 70: 830-835.
APA Dirikoç A, Fakı S, BAŞER H, ÖZDEMİR D, Aydın C, ERSOY R, KILIÇ M, KILIÇARSLAN A, ÇAKIR B (2017). Thyroid malignancy risk in different clinical thyroid diseases. , 1509 - 1519.
Chicago Dirikoç Ahmet,Fakı Sevgul,BAŞER Hüsniye,ÖZDEMİR DİDEM,Aydın Cevdet,ERSOY Reyhan,KILIÇ Mehmet,KILIÇARSLAN Aydan,ÇAKIR Bekir Thyroid malignancy risk in different clinical thyroid diseases. (2017): 1509 - 1519.
MLA Dirikoç Ahmet,Fakı Sevgul,BAŞER Hüsniye,ÖZDEMİR DİDEM,Aydın Cevdet,ERSOY Reyhan,KILIÇ Mehmet,KILIÇARSLAN Aydan,ÇAKIR Bekir Thyroid malignancy risk in different clinical thyroid diseases. , 2017, ss.1509 - 1519.
AMA Dirikoç A,Fakı S,BAŞER H,ÖZDEMİR D,Aydın C,ERSOY R,KILIÇ M,KILIÇARSLAN A,ÇAKIR B Thyroid malignancy risk in different clinical thyroid diseases. . 2017; 1509 - 1519.
Vancouver Dirikoç A,Fakı S,BAŞER H,ÖZDEMİR D,Aydın C,ERSOY R,KILIÇ M,KILIÇARSLAN A,ÇAKIR B Thyroid malignancy risk in different clinical thyroid diseases. . 2017; 1509 - 1519.
IEEE Dirikoç A,Fakı S,BAŞER H,ÖZDEMİR D,Aydın C,ERSOY R,KILIÇ M,KILIÇARSLAN A,ÇAKIR B "Thyroid malignancy risk in different clinical thyroid diseases." , ss.1509 - 1519, 2017.
ISNAD Dirikoç, Ahmet vd. "Thyroid malignancy risk in different clinical thyroid diseases". (2017), 1509-1519.
APA Dirikoç A, Fakı S, BAŞER H, ÖZDEMİR D, Aydın C, ERSOY R, KILIÇ M, KILIÇARSLAN A, ÇAKIR B (2017). Thyroid malignancy risk in different clinical thyroid diseases. Turkish Journal of Medical Sciences, 47(5), 1509 - 1519.
Chicago Dirikoç Ahmet,Fakı Sevgul,BAŞER Hüsniye,ÖZDEMİR DİDEM,Aydın Cevdet,ERSOY Reyhan,KILIÇ Mehmet,KILIÇARSLAN Aydan,ÇAKIR Bekir Thyroid malignancy risk in different clinical thyroid diseases. Turkish Journal of Medical Sciences 47, no.5 (2017): 1509 - 1519.
MLA Dirikoç Ahmet,Fakı Sevgul,BAŞER Hüsniye,ÖZDEMİR DİDEM,Aydın Cevdet,ERSOY Reyhan,KILIÇ Mehmet,KILIÇARSLAN Aydan,ÇAKIR Bekir Thyroid malignancy risk in different clinical thyroid diseases. Turkish Journal of Medical Sciences, vol.47, no.5, 2017, ss.1509 - 1519.
AMA Dirikoç A,Fakı S,BAŞER H,ÖZDEMİR D,Aydın C,ERSOY R,KILIÇ M,KILIÇARSLAN A,ÇAKIR B Thyroid malignancy risk in different clinical thyroid diseases. Turkish Journal of Medical Sciences. 2017; 47(5): 1509 - 1519.
Vancouver Dirikoç A,Fakı S,BAŞER H,ÖZDEMİR D,Aydın C,ERSOY R,KILIÇ M,KILIÇARSLAN A,ÇAKIR B Thyroid malignancy risk in different clinical thyroid diseases. Turkish Journal of Medical Sciences. 2017; 47(5): 1509 - 1519.
IEEE Dirikoç A,Fakı S,BAŞER H,ÖZDEMİR D,Aydın C,ERSOY R,KILIÇ M,KILIÇARSLAN A,ÇAKIR B "Thyroid malignancy risk in different clinical thyroid diseases." Turkish Journal of Medical Sciences, 47, ss.1509 - 1519, 2017.
ISNAD Dirikoç, Ahmet vd. "Thyroid malignancy risk in different clinical thyroid diseases". Turkish Journal of Medical Sciences 47/5 (2017), 1509-1519.